Fount of Information

TriLink BioTechnologies社 October TriLink Messenger




Research News

mRNA-based Therapy for Hereditary Tyrosinemia Type 1 

It is estimated that around 1 in 100,000 adults suffer from Hereditary Tyrosinemia Type 1, a recessive genetic disease of amino acid metabolism.The current standard of care for HT1 involves taking an oral drug, NTBC, which some patients fail to respond to. In this month's Zon blog we are investigating an alternative treatment option that replaces NTBC treatment with the administration of mRNA encoding the wild-type mRNA for FAH.

Read more.PNG
Image1.pngIndividualized self-amplifying mRNA neoantigen vaccines promise improved outcomes for cancer patients
Image2.pngmRNA pioneers: Deserving candidates for a Nobel Prize
TriLink recently manufactured self-amplifying mRNA for a phase I clinical trial, which showed that individualized, T cell inducing vaccines improved outcomes for cancer patients when administered with checkpoint inhibitor therapies. Find out more in our research spotlight.
Read more.PNG

A recent review article points to several mRNA pioneers as deserving candidates for a Nobel Prize and highlights the value of TriLink’s CleanCap® reagent for rapidly producing mRNA in large quantities. Find out more in our latest research spotlight. 


Read more.PNG

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。